Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer ACP Haplotyper Genome Scanner VCMap
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:bucladesine
go back to main search page
Accession:CHEBI:50095 term browser browse the term
Definition:A 3',5'-cyclic purine nucleotide that is the 2'-butanoate ester and 6-N-butanoyl derivative of 3',5'-cyclic AMP.
Synonyms:exact_synonym: (4aR,6R,7R,7aR)-6-(6-butanamido-9H-purin-9-yl)-2-hydroxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl butanoate;   6-N-butanoyl-2'-O-butanoyladenosine 3',5'-(hydrogen phosphate)
 related_synonym: 3',5'-cyclic AMP dibutyrate;   Bt2cAMP;   Formula=C18H24N5O8P;   InChI=1S/C18H24N5O8P/c1-3-5-11(24)22-16-13-17(20-8-19-16)23(9-21-13)18-15(30-12(25)6-4-2)14-10(29-18)7-28-32(26,27)31-14/h8-10,14-15,18H,3-7H2,1-2H3,(H,26,27)(H,19,20,22,24)/t10-,14-,15-,18-/m1/s1;   InChIKey=CJGYSWNGNKCJSB-YVLZZHOMSA-N;   N(6),2'-O-dibutyryl cAMP;   N(6),2'-O-dibutyryl cyclic AMP;   N(6),O(2')-dibutyryl adenosine 3',5'-cyclic monophosphate;   N(6),O(2')-dibutyryl cyclic 3',5'-AMP;   N(6),O(2')-dibutyryladenosine 3',5'-monophosphate;   SMILES=[C@H]12O[C@H]([C@@H]([C@@H]1OP(OC2)(=O)O)OC(=O)CCC)N3C=NC=4C(=NC=NC34)NC(=O)CCC;   bucladesina;   bucladesinum;   dbcAMP;   dibutyryl 3',5'-cyclic AMP;   dibutyryl adenosine 3',5'-cyclic phosphate;   dibutyryl adenosine 3',5'-monophosphate;   dibutyryl cAMP;   dibutyryl cyclic 3',5'-adenylic acid;   dibutyryl cyclic AMP;   dibutyryl cyclic adenosine 3',5'-monophosphate;   dibutyryl-3',5'-AMP;   dibutyryladenosine 3',5'-cyclic monophosphate;   dibutyryladenosine cyclic monophosphate
 alt_id: CHEBI:143000
 xref: Beilstein:871714;   CAS:362-74-3;   Drug_Central:415;   KEGG:D07546;   LINCS:LSM-1926
 xref_mesh: MESH:D003994
 xref: PMID:15231695;   PMID:20353690;   PMID:23335001;   PMID:27022216;   PMID:29963999;   Reaxys:871714;   Wikipedia:Bucladesine

show annotations for term's descendants           Sort by:
 
bucladesine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions ISO [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA] CTD PMID:20083572 PMID:23227865 PMID:23362264 NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015 		JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions EXP Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein] CTD PMID:16452108 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
increases activity
affects localization
increases expression		 EXP
ISO		 Bucladesine inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]
Bucladesine results in increased activity of ABCC2 protein
Bucladesine results in increased expression of ABCC2 mRNA; Bucladesine results in increased expression of ABCC2 protein
Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine results in increased activity of and affects the localization of ABCC2 protein; Dactinomycin inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; verlukast inhibits the reaction [Bucladesine results in increased activity of ABCC2 protein]		 CTD PMID:12029626 PMID:26049102 PMID:29052767 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252 		JBrowse link
G Ache acetylcholinesterase increases activity
increases expression		 EXP Bucladesine results in increased activity of ACHE protein; Bucladesine results in increased activity of ACHE protein alternative form
Bucladesine results in increased expression of ACHE mRNA		 CTD PMID:18514641 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753 		JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ADAMTS1 mRNA CTD PMID:20823114 NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974 		JBrowse link
G Adm adrenomedullin decreases expression ISO Bucladesine results in decreased expression of ADM mRNA CTD PMID:19253104 NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259 		JBrowse link
G Ahr aryl hydrocarbon receptor affects localization
increases activity
multiple interactions		 ISO Bucladesine affects the localization of AHR protein
Bucladesine results in increased activity of AHR protein
Bucladesine affects the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]		 CTD PMID:15972329 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464 		JBrowse link
G Ahrr aryl-hydrocarbon receptor repressor multiple interactions ISO Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHRR mRNA] CTD PMID:21979172 NCBI chr 1:31,603,297...31,698,329
Ensembl chr 1:31,603,297...31,698,329 		JBrowse link
G Ak5 adenylate kinase 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of AK5 mRNA CTD PMID:20823114 NCBI chr 2:257,671,772...257,864,385
Ensembl chr 2:257,671,772...257,864,385 		JBrowse link
G Akap2 A-kinase anchoring protein 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PALM2AKAP2 mRNA CTD PMID:20823114 NCBI chr 5:74,874,245...74,985,789
Ensembl chr 5:74,874,306...74,982,401 		JBrowse link
G Alas1 5'-aminolevulinate synthase 1 multiple interactions ISO [NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA CTD PMID:22859313 NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177 		JBrowse link
G Antxr1 ANTXR cell adhesion molecule 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ANTXR1 mRNA CTD PMID:20823114 NCBI chr 4:118,946,267...119,131,202
Ensembl chr 4:118,946,268...119,131,202 		JBrowse link
G Anxa2 annexin A2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ANXA2 mRNA CTD PMID:20823114 NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594 		JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO 27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; TO-901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol] CTD PMID:20083572 PMID:23227865 NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875 		JBrowse link
G Ar androgen receptor multiple interactions EXP [Quercetin co-treated with Bucladesine] results in increased expression of AR mRNA CTD PMID:23200735 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026 		JBrowse link
G Arhgef2 Rho/Rac guanine nucleotide exchange factor 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ARHGEF2 mRNA CTD PMID:20823114 NCBI chr 2:187,964,100...188,022,847
Ensembl chr 2:187,977,008...188,021,377 		JBrowse link
G Atf1 activating transcription factor 1 multiple interactions ISO Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]] CTD PMID:12164941 NCBI chr 7:141,882,261...141,924,790
Ensembl chr 7:141,882,251...141,924,788 		JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression		 ISO Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ATF2 protein modified form]
Bucladesine results in increased phosphorylation of ATF2 protein		 CTD PMID:26049102 NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951 		JBrowse link
G Atp11a ATPase phospholipid transporting 11A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP11A mRNA CTD PMID:20823114 NCBI chr16:81,990,340...82,100,222
Ensembl chr16:81,990,340...82,100,222 		JBrowse link
G Atp2b1 ATPase plasma membrane Ca2+ transporting 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ATP2B1 mRNA CTD PMID:20823114 NCBI chr 7:41,114,606...41,223,138
Ensembl chr 7:41,114,697...41,220,579 		JBrowse link
G Atp6v0c ATPase H+ transporting V0 subunit C multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP6V0C mRNA CTD PMID:20823114 NCBI chr10:13,537,031...13,543,407
Ensembl chr10:13,537,033...13,542,077 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] CTD PMID:16822680 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207 		JBrowse link
G Bcat1 branched chain amino acid transaminase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BCAT1 mRNA CTD PMID:20823114 NCBI chr 4:179,259,305...179,340,021
Ensembl chr 4:179,259,308...179,339,795 		JBrowse link
G Bckdk branched chain ketoacid dehydrogenase kinase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCKDK mRNA CTD PMID:20823114 NCBI chr 1:199,351,628...199,356,299
Ensembl chr 1:199,351,628...199,356,881 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression		 ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
Bucladesine results in decreased expression of BCL2 protein		 CTD PMID:10697531 PMID:16822680 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374 		JBrowse link
G Bcl2l13 BCL2 like 13 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA CTD PMID:20823114 NCBI chr 4:153,385,200...153,438,096
Ensembl chr 4:153,385,205...153,436,660 		JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions
increases expression		 ISO 1-bromopropane inhibits the reaction [Bucladesine results in increased expression of BDNF mRNA]; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:19189864 PMID:29698629 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210 		JBrowse link
G Bet1l Bet1 golgi vesicular membrane trafficking protein-like multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BET1L mRNA CTD PMID:20823114 NCBI chr 1:213,602,836...213,606,507
Ensembl chr 1:213,602,850...213,605,643 		JBrowse link
G Bicd1 BICD cargo adaptor 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BICD1 mRNA CTD PMID:20823114 NCBI chr 4:184,018,845...184,167,628
Ensembl chr 4:184,019,087...184,165,540 		JBrowse link
G Bmp4 bone morphogenetic protein 4 multiple interactions ISO Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] CTD PMID:20522807 NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740 		JBrowse link
G Bsnd barttin CLCNK type accessory subunit beta multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BSND mRNA CTD PMID:20823114 NCBI chr 5:126,071,849...126,080,647
Ensembl chr 5:126,071,846...126,080,698 		JBrowse link
G C1r complement C1r multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of C1R mRNA CTD PMID:20823114 NCBI chr 4:157,126,060...157,136,825
Ensembl chr 4:157,125,998...157,136,829 		JBrowse link
G Calm1 calmodulin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CALM1 mRNA CTD PMID:20823114 NCBI chr 6:124,217,241...124,225,292
Ensembl chr 6:124,217,241...124,225,292 		JBrowse link
G Calr calreticulin increases stability ISO Bucladesine results in increased stability of CALR protein CTD PMID:9473613 NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666 		JBrowse link
G Capn2 calpain 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAPN2 mRNA CTD PMID:20823114 NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]; Bucladesine promotes the reaction [Hydroxyurea results in increased activity of CASP3 protein] CTD PMID:10697531 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204 		JBrowse link
G Cast calpastatin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CAST mRNA CTD PMID:20823114 NCBI chr 2:1,452,111...1,561,669
Ensembl chr 2:1,452,116...1,561,464 		JBrowse link
G Cav2 caveolin 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAV2 mRNA CTD PMID:20823114 NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO Bucladesine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein] CTD PMID:12538206 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066 		JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA CTD PMID:20823114 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CCNB1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CCNB1 protein CTD PMID:22534328 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221 		JBrowse link
G Ccnd1 cyclin D1 increases expression
multiple interactions		 EXP
ISO		 Bucladesine results in increased expression of CCND1 protein
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] affects the expression of CCND1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 protein		 CTD PMID:16718685 PMID:21693435 PMID:22534328 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325 		JBrowse link
G Ccnd3 cyclin D3 increases expression EXP Bucladesine results in increased expression of CCND3 protein CTD PMID:16718685 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943 		JBrowse link
G Cd69 Cd69 molecule decreases expression ISO Bucladesine results in decreased expression of CD69 protein CTD PMID:25433234 NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084 		JBrowse link
G Cd80 Cd80 molecule multiple interactions ISO Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein] CTD PMID:12538815 NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353 		JBrowse link
G Cdc42bpa CDC42 binding protein kinase alpha multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CDC42BPA mRNA CTD PMID:20823114 NCBI chr13:98,231,326...98,447,762
Ensembl chr13:98,231,326...98,447,762 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions		 EXP
ISO		 Bucladesine results in increased expression of CDKN1A protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CDKN1A protein
GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]		 CTD PMID:16718685 PMID:20823114 PMID:22534328 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression EXP Bucladesine results in increased expression of CDKN1B protein CTD PMID:16718685 PMID:21693435 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression
multiple interactions		 ISO Bucladesine results in increased expression of CEBPB protein
Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of CEBPB protein]		 CTD PMID:19282384 PMID:19698295 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910 		JBrowse link
G Cebpz CCAAT/enhancer binding protein zeta multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CEBPZ mRNA CTD PMID:20823114 NCBI chr 6:1,516,804...1,534,488
Ensembl chr 6:1,516,804...1,534,488 		JBrowse link
G Chat choline O-acetyltransferase multiple interactions
increases expression		 ISO
EXP		 [Bucladesine co-treated with Tretinoin] results in increased activity of CHAT protein; [Tretinoin co-treated with Bucladesine] results in increased activity of CHAT protein
Bucladesine results in increased expression of CHAT protein
Nicotine promotes the reaction [Bucladesine results in increased expression of CHAT protein]		 CTD PMID:16724269 PMID:20361958 PMID:29665406 NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131 		JBrowse link
G Cldn5 claudin 5 increases expression ISO Bucladesine results in increased expression of CLDN5 mRNA CTD PMID:20711499 NCBI chr11:86,356,292...86,357,718
Ensembl chr11:86,356,294...86,357,718 		JBrowse link
G Cngb1 cyclic nucleotide gated channel subunit beta 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CNGB1 mRNA CTD PMID:20823114 NCBI chr19:10,142,440...10,206,618
Ensembl chr19:10,142,496...10,206,681 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:11576339 PMID:16430859 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789 		JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] CTD PMID:11576339 NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217 		JBrowse link
G Col6a2 collagen type VI alpha 2 chain multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A2 mRNA CTD PMID:20823114 NCBI chr20:12,773,472...12,801,179
Ensembl chr20:12,773,427...12,801,180 		JBrowse link
G Col6a3 collagen type VI alpha 3 chain multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A3 mRNA CTD PMID:20823114 NCBI chr 9:97,926,784...98,004,643
Ensembl chr 9:97,926,787...98,004,546 		JBrowse link
G Cox6a2 cytochrome c oxidase subunit 6A2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of COX6A2 mRNA CTD PMID:20823114 NCBI chr 1:199,624,037...199,626,255
Ensembl chr 1:199,624,037...199,624,783 		JBrowse link
G Cplx1 complexin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CPLX1 mRNA CTD PMID:20823114 NCBI chr14:2,194,895...2,226,610
Ensembl chr14:2,194,933...2,226,598 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 increases phosphorylation
multiple interactions		 ISO Bucladesine results in increased phosphorylation of CREB1 protein
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]]
[Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of CREB1 protein]		 CTD PMID:12164941 PMID:18787026 PMID:19282384 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435 		JBrowse link
G Crebbp CREB binding protein multiple interactions ISO Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]
[Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]		 CTD PMID:19282384 PMID:20685861 NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039 		JBrowse link
G Crem cAMP responsive element modulator multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CREM mRNA CTD PMID:20823114 NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888 		JBrowse link
G Cryab crystallin, alpha B multiple interactions EXP Bucladesine inhibits the reaction [arsenite results in increased expression of CRYAB protein] CTD PMID:8769853 NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545 		JBrowse link
G Csf1r colony stimulating factor 1 receptor multiple interactions ISO Bucladesine promotes the reaction [Tretinoin results in increased expression of CSF1R mRNA] CTD PMID:8445950 NCBI chr18:56,414,493...56,458,300
Ensembl chr18:56,414,488...56,458,300 		JBrowse link
G Ctbp1 C-terminal binding protein 1 multiple interactions
affects localization		 ISO Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein]; Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein]
Bucladesine affects the localization of CTBP1 protein		 CTD PMID:18184656 NCBI chr14:82,762,109...82,789,350
Ensembl chr14:82,762,190...82,789,319 		JBrowse link
G Ctbp2 C-terminal binding protein 2 affects localization
multiple interactions		 ISO Bucladesine affects the localization of CTBP2 protein
Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein]		 CTD PMID:18184656 NCBI chr 1:205,001,354...205,030,565
Ensembl chr 1:205,001,396...205,040,755 		JBrowse link
G Ctnnb1 catenin beta 1 increases phosphorylation EXP Bucladesine results in increased phosphorylation of CTNNB1 protein CTD PMID:26964897 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372 		JBrowse link
G Ctps2 CTP synthase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CTPS2 mRNA CTD PMID:20823114 NCBI chr  X:33,383,087...33,522,852
Ensembl chr  X:33,383,087...33,522,836 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 decreases expression ISO Bucladesine results in decreased expression of CXCL12 mRNA CTD PMID:20711499 NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891 		JBrowse link
G Cyb5d1 cytochrome b5 domain containing 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CYB5D1 mRNA CTD PMID:20823114 NCBI chr10:55,993,206...55,997,429
Ensembl chr10:55,995,823...55,997,299 		JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 increases expression
multiple interactions		 EXP
ISO		 Bucladesine results in increased expression of CYP11A1 mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA]		 CTD PMID:21693180 PMID:21979172 PMID:23200735 NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression
increases expression
multiple interactions		 EXP Bucladesine results in decreased expression of CYP17A1 mRNA
Bucladesine results in increased expression of CYP17A1 mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA]		 CTD PMID:21458522 PMID:21693180 PMID:23200735 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions EXP
ISO		 Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]		 CTD PMID:1849469 PMID:16901605 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] CTD PMID:1849469 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression ISO Bucladesine results in increased expression of CYP1B1 mRNA CTD PMID:11559018 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722 		JBrowse link
G Cyp2a3 cytochrome P450, family 2, subfamily a, polypeptide 3 increases expression
multiple interactions		 ISO Bucladesine results in increased expression of CYP2A5 mRNA
NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA]		 CTD PMID:11162586 PMID:22859313 NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO Bucladesine promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol] CTD PMID:8531136 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542 		JBrowse link
G Dcn decorin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein] CTD PMID:20823114 NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323 		JBrowse link
G Ddx27 DEAD-box helicase 27 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DDX27 mRNA CTD PMID:20823114 NCBI chr 3:163,767,236...163,786,408
Ensembl chr 3:163,767,173...163,786,445 		JBrowse link
G Des desmin multiple interactions EXP
ISO		 [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of DES mRNA
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA		 CTD PMID:19089455 PMID:20823114 NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294 		JBrowse link
G Dhx9 DExH-box helicase 9 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DHX9 mRNA CTD PMID:20823114 NCBI chr13:70,885,503...70,922,278
Ensembl chr13:70,885,504...70,922,245 		JBrowse link
G Dio2 iodothyronine deiodinase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DIO2 mRNA CTD PMID:20823114 NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723 		JBrowse link
G Dtymk deoxythymidylate kinase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DTYMK mRNA CTD PMID:20823114 NCBI chr 9:100,921,565...100,930,399
Ensembl chr 9:100,921,565...100,930,399 		JBrowse link
G Eda ectodysplasin-A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EDA mRNA CTD PMID:20823114 NCBI chr  X:69,730,123...70,222,693
Ensembl chr  X:69,730,242...70,220,329 		JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EEF1A1 mRNA CTD PMID:20823114 NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818 		JBrowse link
G Efemp1 EGF containing fibulin extracellular matrix protein 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EFEMP1 mRNA CTD PMID:20823114 NCBI chr14:113,202,382...113,294,993
Ensembl chr14:113,202,419...113,295,014 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egr2 early growth response 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EGR2 mRNA CTD PMID:20823114 NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025 		JBrowse link
G Eno2 enolase 2 multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA CTD PMID:29698629 NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
Ensembl chr 9:157,285,179...157,294,047 		JBrowse link
G Epb41l4a erythrocyte membrane protein band 4.1 like 4A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPB41L4A mRNA CTD PMID:20823114 NCBI chr18:26,570,051...26,788,586
Ensembl chr18:26,570,647...26,658,892 		JBrowse link
G Epha3 Eph receptor A3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPHA3 mRNA CTD PMID:20823114 NCBI chr11:421,253...783,037
Ensembl chr11:421,135...782,954 		JBrowse link
G Esr1 estrogen receptor 1 increases expression
multiple interactions		 EXP Bucladesine results in increased expression of ESR1 mRNA
[Quercetin co-treated with Bucladesine] results in increased expression of ESR1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of ESR1 mRNA]		 CTD PMID:21693180 PMID:23200735 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796 		JBrowse link
G Eya1 EYA transcriptional coactivator and phosphatase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EYA1 mRNA CTD PMID:20823114 NCBI chr 5:4,275,728...4,495,525
Ensembl chr 5:4,373,626...4,513,142 		JBrowse link
G Fads2 fatty acid desaturase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FADS2 mRNA CTD PMID:20823114 NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524 		JBrowse link
G Fas Fas cell surface death receptor increases expression
multiple interactions		 EXP Bucladesine results in increased expression of FAS mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of FAS mRNA]		 CTD PMID:12414803 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790 		JBrowse link
G Fbxo11 F-box protein 11 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXO11 mRNA CTD PMID:20823114 NCBI chr 6:11,662,356...11,737,427
Ensembl chr 6:11,662,356...11,686,682 		JBrowse link
G Fbxw5 F-box and WD repeat domain containing 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXW5 mRNA CTD PMID:20823114 NCBI chr 3:2,726,705...2,731,213
Ensembl chr 3:2,727,254...2,731,212 		JBrowse link
G Fcer2 Fc fragment of IgE receptor II decreases expression ISO Bucladesine results in decreased expression of FCER2 protein CTD PMID:1328389 NCBI chr12:2,233,772...2,245,324
Ensembl chr12:2,233,778...2,245,324 		JBrowse link
G Fgd1 FYVE, RhoGEF and PH domain containing 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FGD1 mRNA CTD PMID:20823114 NCBI chr  X:20,100,942...20,143,871
Ensembl chr  X:20,216,587...20,225,955
Ensembl chr  X:20,216,587...20,225,955 		JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681 		JBrowse link
G Fgf9 fibroblast growth factor 9 multiple interactions ISO FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; FGF9 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] CTD PMID:22798350 NCBI chr15:38,341,657...38,386,945
Ensembl chr15:38,341,089...38,387,316 		JBrowse link
G Filip1l filamin A interacting protein 1-like multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FILIP1L mRNA CTD PMID:20823114 NCBI chr11:45,039,488...45,275,141
Ensembl chr11:45,039,461...45,124,423 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [bisphenol A co-treated with Bucladesine] results in increased methylation of FKBP5 intron; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 protein; [Bucladesine co-treated with Dexamethasone] results in increased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 protein; [fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron; bisphenol A promotes the reaction [[fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron]; Dexamethasone inhibits the reaction [[Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA]; Estradiol inhibits the reaction [[Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA] CTD PMID:26427651 NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020 		JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FN1 mRNA CTD PMID:20823114 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit affects expression
multiple interactions
increases expression		 ISO Bucladesine affects the expression of FOS protein
Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein]
Bucladesine results in increased expression of FOS mRNA; Bucladesine results in increased expression of FOS protein		 CTD PMID:7798212 PMID:9187264 PMID:19282384 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299 		JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FOXO1 mRNA CTD PMID:20823114 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016 		JBrowse link
G Fscn2 fascin actin-bundling protein 2, retinal multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FSCN2 mRNA CTD PMID:20823114 NCBI chr10:109,528,307...109,540,675
Ensembl chr10:109,533,487...109,540,026 		JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 increases expression
multiple interactions		 ISO Bucladesine results in increased expression of G6PC mRNA; Bucladesine results in increased expression of G6PC protein
IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC mRNA]; STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]]		 CTD PMID:22859313 PMID:26064446 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213 		JBrowse link
G Gars glycyl-tRNA synthetase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GARS1 mRNA CTD PMID:20823114 NCBI chr 4:85,235,122...85,276,085
Ensembl chr 4:85,235,172...85,276,044 		JBrowse link
G Gbe1 1,4-alpha-glucan branching enzyme 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GBE1 mRNA CTD PMID:20823114 NCBI chr11:7,210,169...7,485,895
Ensembl chr11:7,210,209...7,485,890 		JBrowse link
G Gbp2 guanylate binding protein 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GBP2 mRNA CTD PMID:20823114 NCBI chr 2:248,276,795...248,293,784
Ensembl chr 2:248,276,709...248,293,784 		JBrowse link
G Gcnt2 glucosaminyl (N-acetyl) transferase 2 (I blood group) multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GCNT2 mRNA CTD PMID:20823114 NCBI chr17:21,634,546...21,677,477
Ensembl chr17:21,634,551...21,739,408 		JBrowse link
G Gdf3 growth differentiation factor 3 affects expression
multiple interactions		 ISO Bucladesine affects the expression of GDF3 mRNA; Bucladesine affects the expression of GDF3 protein
bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 protein]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 protein]		 CTD PMID:31400064 NCBI chr 4:155,417,667...155,422,014
Ensembl chr 4:155,417,004...155,421,998 		JBrowse link
G Gipc1 GIPC PDZ domain containing family, member 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GIPC1 mRNA CTD PMID:20823114 NCBI chr19:24,786,604...24,798,231
Ensembl chr19:24,786,628...24,798,233 		JBrowse link
G Gja1 gap junction protein, alpha 1 multiple interactions
increases expression		 EXP GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein] CTD PMID:11741589 PMID:16718685 NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089 		JBrowse link
G Gpd1 glycerol-3-phosphate dehydrogenase 1 multiple interactions ISO Bucladesine promotes the reaction [Bezafibrate results in increased expression of GPD1 mRNA] CTD PMID:1976021 NCBI chr 7:141,368,928...141,377,931
Ensembl chr 7:141,370,491...141,377,928 		JBrowse link
G Gpkow G patch domain and KOW motifs multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GPKOW mRNA CTD PMID:20823114 NCBI chr  X:15,636,567...15,651,332
Ensembl chr  X:15,636,563...15,651,332 		JBrowse link
G Gpnmb glycoprotein nmb multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GPNMB mRNA CTD PMID:20823114 NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions
increases expression		 ISO KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA1 mRNA] CTD PMID:26049102 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902 		JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression
multiple interactions		 ISO Bucladesine results in increased expression of GSTA2 mRNA
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA2 mRNA]		 CTD PMID:26049102 NCBI chr 8:85,640,081...85,645,621 JBrowse link
G Gsta4 glutathione S-transferase alpha 4 increases expression
multiple interactions		 ISO Bucladesine results in increased expression of GSTA4 mRNA
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA4 mRNA]		 CTD PMID:26049102 NCBI chr 8:85,497,557...85,514,732
Ensembl chr 8:85,497,557...85,518,879 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression ISO Bucladesine results in increased expression of HIF1A mRNA CTD PMID:18591213 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052 		JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA] CTD PMID:20823114 NCBI chr 4:82,124,358...82,127,182
Ensembl chr 4:82,125,406...82,127,066 		JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 increases expression EXP Bucladesine results in increased expression of HSD17B12 mRNA CTD PMID:21458522 NCBI chr 3:82,924,699...83,048,465
Ensembl chr 3:82,924,687...83,048,435 		JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 increases expression EXP Bucladesine results in increased expression of HSD3B1 mRNA CTD PMID:21458522
G Hspb1 heat shock protein family B (small) member 1 increases expression
increases phosphorylation		 EXP
ISO		 Bucladesine results in increased expression of HSP27 protein
Bucladesine results in increased phosphorylation of HSPB1 protein		 CTD PMID:7541446 PMID:10559386 NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049 		JBrowse link
G Htr1a 5-hydroxytryptamine receptor 1A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of HTR1A mRNA CTD PMID:20823114 NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896 		JBrowse link
G Iapp islet amyloid polypeptide increases expression EXP Bucladesine results in increased expression of IAPP mRNA CTD PMID:9142872 NCBI chr 4:176,509,863...176,517,903
Ensembl chr 4:176,510,696...176,516,083 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] CTD PMID:12538815 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059 		JBrowse link
G Id1 inhibitor of DNA binding 1, HLH protein increases expression
multiple interactions		 ISO Bucladesine results in increased expression of ID1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA]		 CTD PMID:20522807 NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718 		JBrowse link
G Ifrd2 interferon-related developmental regulator 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IFRD2 mRNA CTD PMID:20823114 NCBI chr 8:116,343,096...116,348,318
Ensembl chr 8:116,343,096...116,348,314 		JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] CTD PMID:22798350 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression
multiple interactions		 ISO Bucladesine results in increased expression of IGFBP1
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein]		 CTD PMID:12093828 PMID:20823114 PMID:30328349 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP3 mRNA CTD PMID:20823114 NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374 		JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP4 mRNA CTD PMID:20823114 NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578 		JBrowse link
G Ighe immunoglobulin heavy constant epsilon multiple interactions ISO Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]] CTD PMID:12230500 NCBI chr 6:138,066,728...138,068,606 JBrowse link
G Il10 interleukin 10 decreases expression
multiple interactions		 ISO Bucladesine results in decreased expression of IL10
Bucladesine promotes the reaction [Zymosan results in increased expression of IL10 protein]		 CTD PMID:11301049 PMID:19273625 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392 		JBrowse link
G Il12b interleukin 12B multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IL12B mRNA CTD PMID:20823114 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085 		JBrowse link
G Il13 interleukin 13 decreases expression
decreases secretion		 ISO Bucladesine results in decreased expression of IL13 mRNA
Bucladesine results in decreased secretion of IL13 protein		 CTD PMID:16083514 NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]] CTD PMID:8904084 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726 		JBrowse link
G Il23a interleukin 23 subunit alpha increases expression
multiple interactions		 ISO Bucladesine results in increased expression of IL23A mRNA
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of IL23A mRNA		 CTD PMID:19273625 PMID:20823114 NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723 		JBrowse link
G Il2ra interleukin 2 receptor subunit alpha decreases expression ISO Bucladesine results in decreased expression of IL2RA protein CTD PMID:1709825 PMID:25433234 NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein] CTD PMID:11886533 PMID:12230500 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531 		JBrowse link
G Il5 interleukin 5 multiple interactions ISO Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein] CTD PMID:11886533 NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Bucladesine co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] CTD PMID:20388727 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807 		JBrowse link
G Inha inhibin subunit alpha decreases expression
multiple interactions		 EXP Bucladesine results in decreased expression of INHA mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA; Atrazine inhibits the reaction [Bucladesine results in decreased expression of INHA mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA]		 CTD PMID:21693180 PMID:23200735 NCBI chr 9:82,700,482...82,703,383
Ensembl chr 9:82,700,468...82,703,400 		JBrowse link
G Insl3 insulin-like 3 multiple interactions
increases expression		 EXP [Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of INSL3 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA] CTD PMID:21458522 PMID:21693180 PMID:23200735 NCBI chr16:20,120,753...20,122,702
Ensembl chr16:20,121,352...20,122,696 		JBrowse link
G Ints7 integrator complex subunit 7 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of INTS7 mRNA CTD PMID:20823114 NCBI chr13:110,257,571...110,310,413
Ensembl chr13:110,257,571...110,310,413 		JBrowse link
G Irf9 interferon regulatory factor 9 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IRF9 mRNA CTD PMID:20823114 NCBI chr15:34,282,936...34,288,981
Ensembl chr15:34,282,936...34,288,138 		JBrowse link
G Isg20l2 interferon stimulated exonuclease gene 20-like 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ISG20L2 mRNA CTD PMID:20823114 NCBI chr 2:187,302,192...187,311,677
Ensembl chr 2:187,302,192...187,311,676 		JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITGB1 mRNA CTD PMID:20823114 NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535 		JBrowse link
G Itih5 inter-alpha-trypsin inhibitor heavy chain 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITIH5 mRNA CTD PMID:20823114 NCBI chr17:72,035,799...72,055,809
NCBI chr17:72,108,870...72,137,419 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions		 ISO Bucladesine results in increased expression of JUN mRNA; Bucladesine results in increased expression of JUN protein
Bucladesine results in increased expression of JUN protein; Bucladesine results in increased expression of JUN protein modified form
Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein modified form]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein]
[Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]		 CTD PMID:9187264 PMID:18755854 PMID:19282384 PMID:19698295 PMID:26049102 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277 		JBrowse link
G Kat2a lysine acetyltransferase 2A multiple interactions ISO Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein] CTD PMID:18184656 NCBI chr10:88,611,586...88,619,558
Ensembl chr10:88,611,586...88,619,537 		JBrowse link
G Kcnc4 potassium voltage-gated channel subfamily C member 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KCNC4 mRNA CTD PMID:20823114 NCBI chr 2:210,220,908...210,241,447
Ensembl chr 2:210,220,908...210,241,455 		JBrowse link
G Kng2 kininogen 2 increases activity EXP Bucladesine results in increased activity of KNG1 CTD PMID:1334751 NCBI chr11:81,509,185...81,516,759 JBrowse link
G Krt8 keratin 8 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA] CTD PMID:20823114 NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803 		JBrowse link
G Lamb2 laminin subunit beta 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LAMB2 mRNA CTD PMID:20823114 NCBI chr 8:117,268,335...117,280,517
Ensembl chr 8:117,268,337...117,280,517 		JBrowse link
G Ldha lactate dehydrogenase A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LDHA mRNA CTD PMID:20823114 NCBI chr 1:102,900,288...102,909,713
Ensembl chr 1:102,900,286...102,909,707 		JBrowse link
G Lep leptin decreases expression ISO Bucladesine results in decreased expression of LEP mRNA CTD PMID:9002984 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818 		JBrowse link
G Lgals3 galectin 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of LGALS3 mRNA CTD PMID:20823114 NCBI chr15:24,153,602...24,165,537
Ensembl chr15:24,141,651...24,165,537 		JBrowse link
G Lhcgr luteinizing hormone/choriogonadotropin receptor decreases expression
multiple interactions		 EXP Bucladesine results in decreased expression of LHCGR mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA]		 CTD PMID:21693180 PMID:23200735 NCBI chr 6:12,493,182...12,554,482
Ensembl chr 6:12,493,943...12,554,439 		JBrowse link
G Lipe lipase E, hormone sensitive type affects localization
increases activity
increases expression
multiple interactions		 EXP
ISO		 Bucladesine affects the localization of LIPE protein
Bucladesine results in increased activity of LIPE protein
Bucladesine results in increased expression of LIPE mRNA
[Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein; CAY 10499 inhibits the reaction [Bucladesine results in increased activity of and results in increased phosphorylation of LIPE protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]; NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]		 CTD PMID:11160373 PMID:23362264 NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727 		JBrowse link
G Lpar3 lysophosphatidic acid receptor 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LPAR3 mRNA CTD PMID:20823114 NCBI chr 2:252,090,634...252,159,221
Ensembl chr 2:252,090,669...252,159,903 		JBrowse link
G Ltbp1 latent transforming growth factor beta binding protein 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LTBP1 mRNA CTD PMID:20823114 NCBI chr 6:21,203,502...21,600,441
Ensembl chr 6:21,203,502...21,600,451 		JBrowse link
G Ltc4s leukotriene C4 synthase decreases secretion ISO Bucladesine results in decreased secretion of LTC4S protein CTD PMID:16083514 NCBI chr10:35,736,486...35,743,088
Ensembl chr10:35,737,664...35,739,625 		JBrowse link
G Map1a microtubule-associated protein 1A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA CTD PMID:20823114 NCBI chr 3:113,251,918...113,272,193
Ensembl chr 3:113,251,778...113,272,186 		JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA CTD PMID:29698629 NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972 		JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA CTD PMID:20823114 NCBI chr 9:46,657,444...46,782,545
Ensembl chr 9:46,657,575...46,782,545 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation		 ISO 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein
Bucladesine results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK1 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein]]		 CTD PMID:8526880 PMID:19282384 PMID:22875961 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation		 ISO 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein
Bucladesine results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK3 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein]]		 CTD PMID:8526880 PMID:19282384 PMID:22875961 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975 		JBrowse link
G Mgat4b alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MGAT4B mRNA CTD PMID:20823114 NCBI chr10:35,726,501...35,736,338
Ensembl chr10:35,726,544...35,736,338 		JBrowse link
G Mir125a microRNA 125a decreases expression EXP
ISO		 Bucladesine results in decreased expression of MIR125A mRNA CTD PMID:23045399 NCBI chr 1:59,704,827...59,704,911
Ensembl chr 1:59,704,827...59,704,911 		JBrowse link
G Mir145 microRNA 145 decreases expression EXP
ISO		 Bucladesine results in decreased expression of MIR145 mRNA CTD PMID:23045399 NCBI chr18:56,969,907...56,969,994
Ensembl chr18:56,969,907...56,969,994 		JBrowse link
G Mir27b microRNA 27b multiple interactions ISO [Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MIR27B mRNA CTD PMID:30328349 NCBI chr17:823,461...823,557
Ensembl chr17:823,461...823,557 		JBrowse link
G Mir455 microRNA 455 decreases expression EXP
ISO		 Bucladesine results in decreased expression of MIR455 mRNA CTD PMID:23045399 NCBI chr 5:79,097,208...79,097,285
Ensembl chr 5:79,097,208...79,097,285 		JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression EXP Bucladesine results in decreased expression of MKI67 protein CTD PMID:16718685 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MMP2 mRNA CTD PMID:20823114 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611 		JBrowse link
G Mthfd2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTHFD2 mRNA CTD PMID:20823114 NCBI chr 4:115,004,433...115,015,965
Ensembl chr 4:115,004,448...115,015,965 		JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTR mRNA CTD PMID:20823114 NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO Bucladesine results in decreased expression of MYC mRNA; Bucladesine results in decreased expression of MYC protein CTD PMID:7798212 PMID:9187264 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240 		JBrowse link
G Myh9 myosin, heavy chain 9 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYH9 mRNA CTD PMID:20823114 NCBI chr 7:118,740,005...118,792,507
Ensembl chr 7:118,741,110...118,792,625 		JBrowse link
G Myl12a myosin light chain 12A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12A mRNA CTD PMID:20823114 NCBI chr 9:119,325,282...119,333,012
Ensembl chr 9:119,325,283...119,332,967 		JBrowse link
G Myl12b myosin light chain 12B multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12B mRNA CTD PMID:20823114 NCBI chr 9:119,307,168...119,321,500
Ensembl chr 9:119,307,176...119,321,500 		JBrowse link
G Mylk myosin light chain kinase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA CTD PMID:20823114 NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158 		JBrowse link
G Myof myoferlin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYOF mRNA CTD PMID:20823114 NCBI chr 1:256,585,410...256,734,727
Ensembl chr 1:256,585,410...256,734,730 		JBrowse link
G Ncf1 neutrophil cytosolic factor 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NCF1 mRNA CTD PMID:20823114 NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300 		JBrowse link
G Ndst1 N-deacetylase and N-sulfotransferase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NDST1 mRNA CTD PMID:20823114 NCBI chr18:55,951,497...56,014,107
Ensembl chr18:55,955,389...55,992,885 		JBrowse link
G Nefl neurofilament light chain multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA CTD PMID:29698629 NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574 		JBrowse link
G Nefm neurofilament medium chain multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr15:44,855,307...44,860,604
Ensembl chr15:44,855,310...44,860,604 		JBrowse link
G Neurog1 neurogenin 1 multiple interactions
affects expression		 ISO bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 protein]
Bucladesine affects the expression of NEUROG1 mRNA; Bucladesine affects the expression of NEUROG1 protein		 CTD PMID:31400064 NCBI chr17:9,154,656...9,156,175
Ensembl chr17:9,154,656...9,156,175 		JBrowse link
G Nexn nexilin (F actin binding protein) multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NEXN mRNA CTD PMID:20823114 NCBI chr 2:257,452,937...257,484,607
Ensembl chr 2:257,453,347...257,484,587 		JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions
increases response to substance		 ISO [NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC mRNA] CTD PMID:22859313 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996 		JBrowse link
G Ngf nerve growth factor multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453 		JBrowse link
G Nom1 nucleolar protein with MIF4G domain 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NOM1 mRNA CTD PMID:20823114 NCBI chr 4:2,340,034...2,356,427
Ensembl chr 4:2,340,148...2,356,068 		JBrowse link
G Nphp1 nephrocystin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NPHP1 mRNA CTD PMID:20823114 NCBI chr 3:120,316,048...120,370,089
Ensembl chr 3:120,316,047...120,373,500 		JBrowse link
G Nptxr neuronal pentraxin receptor multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NPTXR mRNA CTD PMID:20823114 NCBI chr 7:121,011,678...121,029,754
Ensembl chr 7:121,011,680...121,029,754 		JBrowse link
G Npy neuropeptide Y increases expression EXP Bucladesine results in increased expression of NPY mRNA CTD PMID:19912776 NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097
Ensembl chr 4:79,557,854...79,565,097 		JBrowse link
G Nr0b1 nuclear receptor subfamily 0, group B, member 1 decreases expression
multiple interactions		 ISO Bucladesine results in decreased expression of NR0B1 mRNA; Bucladesine results in decreased expression of NR0B1 protein
Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 protein]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]		 CTD PMID:18787026 PMID:19282384 NCBI chr  X:54,734,385...54,738,513
Ensembl chr  X:54,734,385...54,738,513 		JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 multiple interactions ISO NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] CTD PMID:23362264 NCBI chr 1:100,554,577...100,559,896
Ensembl chr 1:100,554,544...100,559,942 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] CTD PMID:23362264 NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750 		JBrowse link
G Nr2f1 nuclear receptor subfamily 2, group F, member 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NR2F1 mRNA CTD PMID:20823114 NCBI chr 2:5,569,954...5,579,894
Ensembl chr 2:5,569,935...5,579,894 		JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions
increases expression		 ISO NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of NR4A1 protein] CTD PMID:18787026 PMID:19282384 NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216 		JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 multiple interactions ISO Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]
NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]		 CTD PMID:18184656 PMID:18787026 NCBI chr 3:22,998,900...23,020,441
Ensembl chr 3:22,999,616...23,020,441 		JBrowse link
G Nrip1 nuclear receptor interacting protein 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NRIP1 mRNA CTD PMID:20823114 NCBI chr11:14,658,225...14,742,478
Ensembl chr11:14,658,225...14,741,563 		JBrowse link
G Nt5e 5' nucleotidase, ecto multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NT5E mRNA CTD PMID:20823114 NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696 		JBrowse link
G Ntf3 neurotrophin 3 increases expression EXP Bucladesine results in increased expression of NTF3 protein CTD PMID:19854260 NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886 		JBrowse link
G Nts neurotensin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NTS mRNA CTD PMID:20823114 NCBI chr 7:44,111,594...44,120,998
Ensembl chr 7:44,111,151...44,121,130 		JBrowse link
G Nup155 nucleoporin 155 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NUP155 mRNA CTD PMID:20823114 NCBI chr 2:57,206,665...57,258,242
Ensembl chr 2:57,206,613...57,258,295 		JBrowse link
G Odc1 ornithine decarboxylase 1 multiple interactions
decreases activity		 ISO 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [Bucladesine results in decreased activity of ODC1 protein] CTD PMID:6284819 NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927 		JBrowse link
G Ogfrl1 opioid growth factor receptor-like 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OGFRL1 mRNA CTD PMID:20823114 NCBI chr 9:29,634,178...29,647,903
Ensembl chr 9:29,634,179...29,647,903 		JBrowse link
G Olr1201 olfactory receptor 1201 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OR8B8 mRNA CTD PMID:20823114 NCBI chr 8:40,383,997...40,384,929
Ensembl chr 8:40,383,918...40,384,966 		JBrowse link
G P4hb prolyl 4-hydroxylase subunit beta multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of P4HB mRNA CTD PMID:20823114 NCBI chr10:109,736,459...109,748,070
Ensembl chr10:109,736,458...109,747,987 		JBrowse link
G Paep progestagen associated endometrial protein multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PAEP mRNA CTD PMID:20823114 NCBI chr 3:2,935,396...2,938,883 JBrowse link
G Pax6 paired box 6 multiple interactions
affects expression		 ISO bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 protein]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 protein]
Bucladesine affects the expression of PAX6 mRNA; Bucladesine affects the expression of PAX6 protein		 CTD PMID:31400064 NCBI chr 3:95,700,241...95,728,682
Ensembl chr 3:95,707,386...95,728,624 		JBrowse link
G Pcdh18 protocadherin 18 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDH18 mRNA CTD PMID:20823114 NCBI chr 2:138,819,957...138,833,932
Ensembl chr 2:138,819,960...138,833,933 		JBrowse link
G Pcdhb5 protocadherin beta 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDHB4 mRNA CTD PMID:20823114 NCBI chr18:30,398,113...30,400,695
Ensembl chr18:30,398,113...30,400,695 		JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions
increases expression		 ISO
EXP		 Metformin inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA]
Lithium Chloride inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA]		 CTD PMID:1371108 PMID:24428821 NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871 		JBrowse link
G Pdgfa platelet derived growth factor subunit A decreases expression ISO Bucladesine results in decreased expression of PDGFA mRNA CTD PMID:1650039 NCBI chr12:17,734,141...17,756,186
Ensembl chr12:17,734,133...17,755,285 		JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PDK1 mRNA CTD PMID:20823114 NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027 		JBrowse link
G Pf4 platelet factor 4 increases expression
multiple interactions		 ISO Bucladesine results in increased expression of PF4 mRNA
[Bucladesine co-treated with Tetrachlorodibenzodioxin] results in increased expression of PF4 mRNA		 CTD PMID:21979172 NCBI chr14:18,848,549...18,849,258
Ensembl chr14:18,848,549...18,849,258 		JBrowse link
G Pgrmc2 progesterone receptor membrane component 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PGRMC2 mRNA CTD PMID:20823114 NCBI chr 2:127,986,106...128,002,005
Ensembl chr 2:127,986,109...128,002,005 		JBrowse link
G Pitpnc1 phosphatidylinositol transfer protein, cytoplasmic 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PITPNC1 mRNA CTD PMID:20823114 NCBI chr10:95,429,879...95,697,734 JBrowse link
G Pkd2l1 polycystin 2 like 1, transient receptor potential cation channel multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PKD2L1 mRNA CTD PMID:20823114 NCBI chr 1:263,922,201...263,959,318
Ensembl chr 1:263,922,201...263,959,318 		JBrowse link
G Plat plasminogen activator, tissue type multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLAT mRNA CTD PMID:20823114 NCBI chr16:74,098,263...74,122,897
Ensembl chr16:74,098,260...74,122,889 		JBrowse link
G Plekhg3 pleckstrin homology and RhoGEF domain containing G3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLEKHG3 mRNA CTD PMID:20823114 NCBI chr 6:99,612,993...99,655,753
Ensembl chr 6:99,625,306...99,655,362 		JBrowse link
G Plin1 perilipin 1 increases expression
multiple interactions		 ISO Bucladesine results in increased expression of PLIN1 mRNA
LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]		 CTD PMID:23362264 NCBI chr 1:141,458,907...141,470,927
Ensembl chr 1:141,458,181...141,471,010 		JBrowse link
G Pls3 plastin 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PLS3 mRNA CTD PMID:20823114 NCBI chr  X:119,030,311...119,124,268
Ensembl chr  X:119,030,419...119,124,250 		JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions
increases activity		 ISO Ascorbic Acid inhibits the reaction [Bucladesine results in increased activity of PMP22 promoter] CTD PMID:15034573 NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583 		JBrowse link
G Pnpla6 patatin-like phospholipase domain containing 6 increases expression
multiple interactions		 ISO Bucladesine results in increased expression of PNPLA6 mRNA
Bucladesine results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein]		 CTD PMID:20380879 NCBI chr12:2,068,749...2,098,139
Ensembl chr12:2,069,959...2,097,904 		JBrowse link
G Pomc proopiomelanocortin increases expression ISO Bucladesine results in increased expression of POMC mRNA; Bucladesine results in increased expression of POMC protein modified form CTD PMID:1325994 NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 affects expression
multiple interactions		 ISO Bucladesine affects the expression of POU5F1 mRNA; Bucladesine affects the expression of POU5F1 protein
bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 protein]		 CTD PMID:31400064 NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression
multiple interactions		 ISO Bucladesine results in increased expression of PPARG protein
[ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein		 CTD PMID:19698295 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression
multiple interactions		 ISO Bucladesine results in increased expression of PPARGC1A mRNA; Bucladesine results in increased expression of PPARGC1A protein
IL22 protein inhibits the reaction [Bucladesine results in increased expression of PPARGC1A protein]; Metformin inhibits the reaction [Bucladesine results in increased expression of PPARGC1A mRNA]		 CTD PMID:24428821 PMID:26064446 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009 		JBrowse link
G Ppia peptidylprolyl isomerase A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PPIA mRNA CTD PMID:20823114 NCBI chr14:86,673,775...86,677,443
Ensembl chr14:86,673,775...86,677,443 		JBrowse link
G Prima1 proline rich membrane anchor 1 increases expression EXP Bucladesine results in increased expression of PRIMA1 mRNA CTD PMID:18514641 NCBI chr 6:127,075,954...127,127,985
Ensembl chr 6:127,075,954...127,127,413 		JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha multiple interactions
increases activity		 EXP KT 5720 inhibits the reaction [Bucladesine results in increased activity of PRKACA protein] CTD PMID:31300867 NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860 		JBrowse link
G Prl prolactin multiple interactions ISO [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL protein CTD PMID:20823114 PMID:30328349 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299 		JBrowse link
G Prss12 serine protease 12 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PRSS12 mRNA CTD PMID:20823114 NCBI chr 2:227,657,983...227,717,884
Ensembl chr 2:227,657,983...227,717,884 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]		 CTD PMID:11095985 PMID:12164941 PMID:24003391 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335 		JBrowse link
G Ptk7 protein tyrosine kinase 7 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTK7 mRNA CTD PMID:20823114 NCBI chr 9:16,662,588...16,729,888
Ensembl chr 9:16,702,460...16,729,030 		JBrowse link
G Ptpa protein phosphatase 2 phosphatase activator multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTPA mRNA CTD PMID:20823114 NCBI chr 3:8,982,122...9,012,585
Ensembl chr 3:8,982,122...9,012,585 		JBrowse link
G Rab1b RAB1B, member RAS oncogene family multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB1B mRNA CTD PMID:20823114 NCBI chr 1:220,483,529...220,491,469
Ensembl chr 1:220,480,834...220,491,469 		JBrowse link
G Rab31 RAB31, member RAS oncogene family multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB31 mRNA CTD PMID:20823114 NCBI chr 9:113,370,072...113,504,606
Ensembl chr 9:113,370,033...113,504,605 		JBrowse link
G Ran RAN, member RAS oncogene family multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RAN mRNA CTD PMID:20823114 NCBI chr12:31,319,556...31,324,105
Ensembl chr12:31,320,624...31,323,810 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases activity
decreases phosphorylation
multiple interactions		 ISO
EXP		 Bucladesine results in decreased activity of RB1 protein
Bucladesine results in decreased phosphorylation of RB1 protein
Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]		 CTD PMID:10697531 PMID:16718685 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342 		JBrowse link
G Ren renin increases secretion
increases expression		 ISO Bucladesine results in increased secretion of REN protein
Bucladesine results in increased expression of REN mRNA		 CTD PMID:9256163 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151 		JBrowse link
G Ret ret proto-oncogene multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RET mRNA CTD PMID:20823114 NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372 		JBrowse link
G Rgs10 regulator of G-protein signaling 10 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RGS10 mRNA CTD PMID:20823114 NCBI chr 1:199,782,076...199,823,440
Ensembl chr 1:199,782,078...199,823,386 		JBrowse link
G Rhobtb3 Rho-related BTB domain containing 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RHOBTB3 mRNA CTD PMID:20823114 NCBI chr 2:2,627,655...2,683,305
Ensembl chr 2:2,627,393...2,683,116 		JBrowse link
G Rin1 Ras and Rab interactor 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RIN1 mRNA CTD PMID:20823114 NCBI chr 1:220,335,036...220,342,319
Ensembl chr 1:220,335,254...220,342,297
Ensembl chr 1:220,335,254...220,342,297 		JBrowse link
G Rpn1 ribophorin I multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPN1 mRNA CTD PMID:20823114 NCBI chr 4:119,997,232...120,018,687
Ensembl chr 4:119,997,268...120,018,679 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPS6KB1 mRNA CTD PMID:20823114 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364 		JBrowse link
G Rpsa ribosomal protein SA multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RPSA mRNA CTD PMID:20823114 NCBI chr 8:128,806,053...128,809,987
Ensembl chr 8:128,806,129...128,809,986 		JBrowse link
G S100a14 S100 calcium binding protein A14 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of S100A14 mRNA CTD PMID:20823114 NCBI chr 2:189,913,433...189,919,947 JBrowse link
G Saraf store-operated calcium entry-associated regulatory factor multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA CTD PMID:20823114 NCBI chr16:61,735,189...61,753,438
Ensembl chr16:61,735,181...61,753,476 		JBrowse link
G Scamp4 secretory carrier membrane protein 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SCAMP4 mRNA CTD PMID:20823114 NCBI chr 7:11,969,720...11,982,141
Ensembl chr 7:11,969,720...11,982,141 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions
increases expression		 ISO
EXP		 LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA] CTD PMID:23045399 PMID:23362264 NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455 		JBrowse link
G Sdcbp syndecan binding protein multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SDCBP mRNA CTD PMID:20823114 NCBI chr 5:19,471,664...19,498,499
Ensembl chr 5:19,471,664...19,498,485 		JBrowse link
G Selenot selenoprotein T multiple interactions
increases expression		 EXP 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA]; nickel chloride inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA] CTD PMID:18198219 NCBI chr 2:148,765,412...148,781,080
Ensembl chr 2:148,765,412...148,780,276 		JBrowse link
G Sema3a semaphorin 3A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SEMA3A mRNA CTD PMID:20823114 NCBI chr 4:18,170,375...18,545,190
Ensembl chr 4:18,178,656...18,396,035 		JBrowse link
G Septin11 septin 11 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SEPTIN11 mRNA CTD PMID:20823114 NCBI chr14:16,369,544...16,405,645
Ensembl chr14:16,369,544...16,452,998 		JBrowse link
G Sfn stratifin multiple interactions ISO [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of SFN mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein CTD PMID:22534328 NCBI chr 5:151,823,422...151,824,937
Ensembl chr 5:151,823,887...151,824,633 		JBrowse link
G Slc18a3 solute carrier family 18 member A3 increases expression
multiple interactions		 EXP Bucladesine results in increased expression of SLC18A3 protein
Nicotine promotes the reaction [Bucladesine results in increased expression of SLC18A3 protein]		 CTD PMID:20361958 NCBI chr16:8,682,668...8,685,529
Ensembl chr16:8,682,669...8,685,529 		JBrowse link
G Slc2a1 solute carrier family 2 member 1 multiple interactions ISO [Progesterone co-treated with Bucladesine] results in increased expression of SLC2A1 protein CTD PMID:18948400 NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897 		JBrowse link
G Slc2a5 solute carrier family 2 member 5 multiple interactions ISO Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA] CTD PMID:12820898 NCBI chr 5:167,142,182...167,174,203
Ensembl chr 5:167,141,875...167,174,310 		JBrowse link
G Smad6 SMAD family member 6 multiple interactions ISO Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] CTD PMID:20522807 NCBI chr 8:68,897,746...68,967,221
Ensembl chr 8:68,898,296...68,966,108 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases expression
increases activity		 ISO Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of SOD2 mRNA]; protein kinase inhibitor peptide inhibits the reaction [Bucladesine results in increased activity of SOD2 protein] CTD PMID:12093828 PMID:20685861 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587 		JBrowse link
G Sox1 SRY-box transcription factor 1 multiple interactions
affects expression		 ISO bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 protein]
Bucladesine affects the expression of SOX1 mRNA; Bucladesine affects the expression of SOX1 protein		 CTD PMID:31400064
G Srsf7 serine and arginine rich splicing factor 7 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SRSF7 mRNA CTD PMID:20823114 NCBI chr 6:2,879,312...2,886,505
Ensembl chr 6:2,880,518...2,886,465 		JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions
increases expression
decreases expression		 ISO
EXP		 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [[TO-901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] which results in increased abundance of Progesterone; [Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone; [Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; [TO-901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[TO-901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[TO-901317 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [TO-901317 results in increased expression of STAR mRNA]]; Bucladesine promotes the reaction [TO-901317 promotes the reaction [[LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [TO-901317 promotes the reaction [[LG 100268 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [TO-901317 promotes the reaction [LG 100268 results in increased expression of STAR mRNA]]; Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA; Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein; CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; lead acetate inhibits the reaction [Bucladesine results in increased expression of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Tetradecanoylphorbol Acetate promotes the reaction [[Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]]
Bucladesine results in increased expression of STAR mRNA; Bucladesine results in increased expression of STAR protein
Bucladesine results in decreased expression of STAR mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA]		 CTD PMID:10964798 PMID:10993823 PMID:11213355 PMID:18755854 PMID:18787026 PMID:19253104 PMID:19282384 PMID:19698295 PMID:20083572 PMID:21047949 PMID:21693180 PMID:21979172 PMID:23200735 PMID:23362264 NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]] CTD PMID:26064446 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233 		JBrowse link
G Stk38 serine/threonine kinase 38 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of STK38 mRNA CTD PMID:20823114 NCBI chr20:6,224,300...6,257,613
Ensembl chr20:6,224,296...6,257,604 		JBrowse link
G Sulf1 sulfatase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SULF1 mRNA CTD PMID:20823114 NCBI chr 5:5,999,520...6,186,901
Ensembl chr 5:5,999,475...6,186,329 		JBrowse link
G Tagln transgelin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA CTD PMID:20823114 NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357 		JBrowse link
G Tcea1 transcription elongation factor A1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TCEA1 mRNA CTD PMID:20823114 NCBI chr 5:14,511,183...14,548,494
Ensembl chr 5:14,511,183...14,548,429 		JBrowse link
G Tert telomerase reverse transcriptase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TERT mRNA CTD PMID:20823114 NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476 		JBrowse link
G Testin testin gene decreases expression
multiple interactions		 EXP Bucladesine results in decreased expression of TESTIN mRNA
Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]; lonidamine inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]		 CTD PMID:11090432 NCBI chr17:4,194,796...4,225,376
Ensembl chr17:4,212,890...4,225,376 		JBrowse link
G Tfrc transferrin receptor decreases expression ISO Bucladesine results in decreased expression of TFRC protein CTD PMID:2989362 NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] CTD PMID:11576339 PMID:16430859 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199 		JBrowse link
G Tgm2 transglutaminase 2 multiple interactions ISO [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein; [phenylsaligenin cyclic phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein CTD PMID:32749514 NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257 		JBrowse link
G Th tyrosine hydroxylase increases expression EXP Bucladesine results in increased expression of TH mRNA CTD PMID:19912776 NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287 		JBrowse link
G Tjp1 tight junction protein 1 multiple interactions EXP Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of TJP1 protein] CTD PMID:16716901 NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469 		JBrowse link
G Tnc tenascin C multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TNC mRNA CTD PMID:20823114 NCBI chr 5:79,789,686...79,874,555
Ensembl chr 5:79,789,671...79,874,671 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP		 Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
Bucladesine inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Bucladesine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
Bucladesine inhibits the reaction [Zymosan results in increased expression of TNF protein]		 CTD PMID:11301049 PMID:12509806 PMID:12538815 PMID:15081246 PMID:20388727 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
Ensembl chr20:5,189,390...5,192,000 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of TP53 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein CTD PMID:22534328 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449 		JBrowse link
G Tpi1 triosephosphate isomerase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TPI1 mRNA CTD PMID:20823114 NCBI chr 4:157,328,375...157,331,905
Ensembl chr 4:157,328,379...157,331,905
Ensembl chr 9:157,328,379...157,331,905 		JBrowse link
G Tpsg1 tryptase gamma 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TPSG1 mRNA CTD PMID:20823114 NCBI chr10:14,724,531...14,731,259
Ensembl chr10:14,727,180...14,731,086 		JBrowse link
G Txn1 thioredoxin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TXN mRNA CTD PMID:20823114 NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752 		JBrowse link
G Ube2d4 ubiquitin-conjugating enzyme E2D 4 (putative) multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of UBE2D4 mRNA CTD PMID:20823114 NCBI chr14:2,933,097...2,934,571
Ensembl chr14:2,933,100...2,934,571 		JBrowse link
G Ucp1 uncoupling protein 1 increases expression
multiple interactions		 EXP Bucladesine results in increased expression of UCP1 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of UCP1 mRNA]		 CTD PMID:12414803 NCBI chr19:24,456,976...24,464,808
Ensembl chr19:24,456,976...24,464,807 		JBrowse link
G Ugcg UDP-glucose ceramide glucosyltransferase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of UGCG mRNA CTD PMID:20823114 NCBI chr 5:76,376,722...76,419,564
Ensembl chr 5:76,386,836...76,419,560 		JBrowse link
G Usp12 ubiquitin specific peptidase 12 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of USP12 mRNA CTD PMID:20823114 NCBI chr12:10,037,686...10,087,685
Ensembl chr12:10,063,117...10,087,685 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Bucladesine results in increased expression of VEGFA mRNA CTD PMID:18591213 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681 		JBrowse link
G Vim vimentin multiple interactions ISO [Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein CTD PMID:20823114 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212 		JBrowse link
G Vps39 VPS39 subunit of HOPS complex multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VPS39 mRNA CTD PMID:20823114 NCBI chr 3:112,087,213...112,125,307
Ensembl chr 3:112,087,677...112,125,318 		JBrowse link
G Wnt5a Wnt family member 5A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WNT5A mRNA CTD PMID:20823114 NCBI chr16:4,469,451...4,490,271
Ensembl chr16:4,469,468...4,489,860 		JBrowse link
G Wwtr1 WW domain containing transcription regulator 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of WWTR1 mRNA CTD PMID:20823114 NCBI chr 2:147,577,149...147,693,033
Ensembl chr 2:147,577,089...147,693,082 		JBrowse link
G Zbtb45 zinc finger and BTB domain containing 45 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZBTB45 mRNA CTD PMID:20823114 NCBI chr 1:65,563,999...65,568,301
Ensembl chr 1:65,564,173...65,568,300 		JBrowse link
G Zscan10 zinc finger and SCAN domain containing 10 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN10 mRNA CTD PMID:20823114 NCBI chr10:12,929,471...12,939,439
Ensembl chr10:12,929,471...12,939,435 		JBrowse link
G Zscan20 zinc finger and SCAN domain containing 20 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ZSCAN20 mRNA CTD PMID:20823114 NCBI chr 5:146,760,822...146,788,945
Ensembl chr 5:146,762,683...146,787,676 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19770
    role 19720
      biological role 19720
        pharmacological role 18830
          agonist 18253
            bucladesine 301
Path 2
Term Annotations click to browse term
  CHEBI ontology 19770
    subatomic particle 19768
      composite particle 19768
        hadron 19768
          baryon 19768
            nucleon 19768
              atomic nucleus 19768
                atom 19768
                  main group element atom 19662
                    p-block element atom 19662
                      chalcogen 19391
                        oxygen atom 19354
                          oxygen molecular entity 19354
                            hydroxides 19077
                              oxoacid 18278
                                pnictogen oxoacid 10308
                                  phosphorus oxoacid 9229
                                    phosphoric acids 7949
                                      phosphoric acid 7949
                                        phosphoric acid derivative 7630
                                          phosphate 7630
                                            organic phosphate 7629
                                              carbohydrate phosphate 1713
                                                phospho sugar 1638
                                                  aldose phosphate 1636
                                                    aldopentose phosphate 1630
                                                      ribose phosphate 1625
                                                        ribonucleotide 1586
                                                          purine ribonucleotide 1558
                                                            adenyl ribonucleotide 1258
                                                              3',5'-cyclic AMP 1081
                                                                bucladesine 301
paths to the root